Vanderbilt Research Trending Archives
Jan. 19, 2017—The duration of exposure to daylight, or the “photoperiod,” may affect development of seasonal affective disorder by programming serotonin neurons in the brain, according to Vanderbilt University researchers.
Dec. 16, 2016—Artificial kidneys, gay-straight alliances and junkyard batteries captured readers' attention in 2016.
Dec. 15, 2016—The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2016.
Dec. 6, 2016—A new microfluidic device containing human cells that faithfully mimics the behavior of the blood-brain barrier is providing new insights into brain inflammation, the silent killer.
Oct. 27, 2016—A team of Vanderbilt scientists have genetically modified luciferase, the enzyme that produces bioluminescence, so that it acts as an optical sensor that records activity in brain cells.
Oct. 13, 2016—A Vanderbilt University study published today in the Journal of Clinical Psychiatry may help patients prescribed higher doses of certain antidepressants feel better about attributed cardiac risks.
Oct. 6, 2016—Scientists in the Vanderbilt Epidemiology Center (VEC) and Vanderbilt-Ingram Cancer Center (VICC) have been awarded a grant to plan and develop a Regional Center of Research Excellence in non-communicable diseases in Vietnam.
Sep. 15, 2016—A research team led by structural biologists from Vanderbilt University has come up with the first detailed molecular explanation for a factor that may contribute to the so-called cystic fibrosis (CF) “gender gap.”
Sep. 9, 2016—As part of the national Cancer Moonshot initiative, a Blue Ribbon Panel (BRP) of cancer leaders, including four from Vanderbilt-Ingram Cancer Center, has delivered a series of recommendations to accelerate the pace of cancer prevention efforts and scientific discovery.
Sep. 1, 2016—A consortium led by Vanderbilt University Medical Center (VUMC) researchers has received funding as it makes plans for a multicenter trial that could determine whether deep brain stimulation (DBS) slows the progression of Parkinson’s disease in early-stage patients.